A feasibility double-blind trial of levothyroxine vs. levothyroxine-liothyronine in postsurgical hypothyroidism.
Giao Q Phan, Sahzene Yavuz, Angeliki M Stamatouli...
https://pubmed.ncbi.nlm.nih.gov/40130156/Actively Recruiting
Led by M. Medici · Updated on 2025-02-26
600
Participants Needed
19
Research Sites
N/A
Total Duration
Researchers are investigating the effectiveness of adding liothyronine LT3 to levothyroxine LT4 treatment in patients with autoimmune hypothyroidism who continue to experience severe tiredness despite having normalized thyroid hormone levels on LT4 alone. This study addresses the problem that LT4 monotherapy may not fully replicate the natural balance of thyroid hormones, as healthy individuals produce some T3 directly. The trial also explores whether certain genetic factors influence response to combination therapy. The study begins with a run-in period where all participants switch to a standardized generic LT4 to stabilize thyroid hormone levels. After confirming normal TSH levels and persistent tiredness, participants enter a one-year randomized, double-blind trial comparing LT4LT3 combination therapy to LT4 with placebo. The LT4LT3 group takes LT4 once daily and LT3 twice daily at a set ratio. Visits occur at baseline and multiple times over the year to adjust doses and monitor health. Participants undergo physical exams, ECGs, blood tests, and complete questionnaires about tiredness, quality of life, and medical resource use throughout the study. Additional measures include bone markers, scans, cardiovascular and metabolic assessments, and neurocognitive tests in subgroups. The main outcome is the change in tiredness scores over 52 weeks, with safety and genetic factors also evaluated. The total study duration includes the run-in and treatment phases, lasting several months to over a year.
CONDITIONS
LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.
M
Marco Medici, MD PhD
L
Lizette Blankers, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
M. Medici
Lead Sponsor
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 to 8 months
Participants switch to a blinded generic LT4 medication. Serum TSH levels are measured every 8 weeks and medication doses adjusted as needed to reach and maintain normal TSH levels. This period ensures stable thyroid hormone levels before randomization.
Visits every 8 weeks for TSH measurement and possible dose adjustments
Duration - 52 weeks
Participants are randomized to receive either LT4/LT3 combination therapy or LT4 with placebo in a 1-year double-blind trial. Serum TSH is monitored and doses adjusted to maintain normal levels. Questionnaires on tiredness, quality of life, and medical consumption are completed at each visit. Blood tests, ECG, bone markers, DXA scans, and neurocognitive tests are performed at specific times to assess treatment effects.
Visits at baseline, and weeks 8, 16, 26, 39, and 52
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Giao Q Phan, Sahzene Yavuz, Angeliki M Stamatouli...
https://pubmed.ncbi.nlm.nih.gov/40130156/M. Medici
Lead Sponsor
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor